Follow the Inhibrx Biosciences, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.7bn. The latest transaction was filed on 8 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Lappe Mark. Every trade is openly available.
31
Insider Decl.
n/a
Thresholds
€7m
20 ops.
Buy Volume
€9m
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Inhibrx Biosciences, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$266.67.
55Σ signal
Buys €7m€9m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
49,284 shares@ US$17.2334.0% of flowCommon StockSEC:0002007919-24-000008:0
Canonical exit: 3 Sept 2024 (T+90)
25 of 31 declarations
Acerca de Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias innovadoras para el tratamiento del cáncer y otras enfermedades graves. La empresa cotiza en NASDAQ bajo el ticker INBX.